Novo Nordisk CEO: No Intention to Lower Wegovy Prices

Novo Nordisk CEO Mike Doustdar stated in an interview with Bloomberg Television that the company has no plans to further reduce prices for its obesity drug Wegovy. Doustdar noted that the drug boosted sales in the first quarter and that the company remains 'very optimistic' about the product despite competition. The CEO emphasized that Wegovy continues to see strong demand despite competition from Eli Lilly, and the company does not foresee any price cuts. Doustdar said the current pricing strategy will be maintained and that aggressive price reductions are not necessary to protect market share. Novo Nordisk continues to work on other obesity treatments in addition to Wegovy. The company aims to expand its product portfolio by maintaining R&D investments in an increasingly competitive environment. This is not investment advice.

📊 LLY — Piyasa Yorumu

▼ down · 70%

The news indicates that Novo Nordisk will not reduce Wegovy prices, signaling the company will maintain its strong pricing strategy against competitor LLY. LLY's technical indicators are already weak: RSI at 33 is near oversold territory, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. A 4.1% decline in the last 24 hours confirms ongoing selling pressure. In the short term, this negative news and technical outlook suggest that downward movement in LLY may continue.

RSI 14

33.3

MACD

-4.43

24h Δ

-4.13%

📊 NVO — Piyasa Yorumu

▲ up · 60%

The news confirms that Wegovy prices will not be reduced, supporting the company's profitability expectations. Technical indicators also back this positive view: the RSI at 62.5 is not approaching overbought territory, the MACD is above zero, and the stock is trading above both the SMA20 and SMA50. In the short term, an upward trend may continue, but the price being close to the SMA20 and the MACD remaining below the signal line warrant caution.

RSI 14

62.5

MACD

0.34

24h Δ

2.16%

Canlı Grafikler